Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

AI-Driven Target & Binder Discovery Services for CAR/TCR Development

Online Inquiry

Background Service What We Can Offer Workflow Specialty Services Highlights FAQs Contact

Creative Biolabs provides an AI-Driven Target & Binder Discovery Service to address challenges in immunotherapy development, including high off-target toxicity risks, limited target availability in solid tumors, and the labor-intensive process of experimental binder screening. This service enables the identification of exclusive tumor antigens and the design of high-affinity binders with clinical-grade precision. By integrating deep learning architectures, 3D structural modeling, and high-throughput immunogenomics, Creative Biolabs accelerates the translation of raw genomic data into optimized CAR and TCR constructs, streamlining the discovery-to-clinic workflow.

Introduction

The field of cancer immunotherapy has shifted toward personalized targets that bypass central immune tolerance. While traditional experimental identification is resource-intensive, AI/ML models now offer high-throughput alternatives for characterizing the multidimensional nature of tumor omics data. By modeling the biophysical properties of pMHC-TCR interactions, these tools enable the discovery of immunogenic neoantigens and high-affinity binders with unprecedented speed.

Fig.1 Machine learning frameworks for de novo binder design and antibody engineering. (OA Literature) Fig.1 AI-driven approaches for the de novo design of binders and antibodies.1

Service

At Creative Biolabs, we bridge the gap between complex multi-omics data and functional therapeutic candidates. Our service delivers high-confidence, tumor-specific antigens and binders designed to minimize "on-target, off-tumor" effects while maximizing T-cell activation and persistence. Our integrated computational platform enables comprehensive antigen discovery through AI-driven prioritization of tumor-specific antigens with minimal off-target risks, supports high-affinity binder selection by predicting and optimizing scFv, antibody fragments, or TCR sequences for superior specificity and stability, and provides structural and functional insights via computational modeling to assess binding interfaces, stability, and expression potential.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs leverages a suite of technologies to support CAR/TCR target and binder discovery:

AI-Based Target Screening Platforms: Multi-omics integration for antigen prioritization and safety assessment.
Computational Binder Modeling: Prediction of scFv, antibody fragments, and TCR sequences for binding affinity and stability.
Structural Simulation Tools: Protein folding and docking simulations for interface optimization.
Custom Data Analytics: Statistical scoring, risk evaluation, and candidate ranking for decision-making.

Our Workflow

Required Starting Materials: To initiate the service, clients typically provide raw patient-specific data or a list of pre-identified candidate protein sequences.

Workflow of AI-Driven Target & Binder Discovery Service. (Creative Biolabs Original)

Final Deliverables: You will receive a Detailed Target Validation Report and a Binder Characterization Data Package containing predicted binding affinities, structural docking models, and immunogenicity scores.

Specialty Services

AI-Integrated Tumor Antigen Discovery Service for CAR-T Development

Creative Biolabs leverages deep learning and multi-omics integration to identify novel tumor-associated surface antigens. Our AI-powered platform accelerates target discovery and prioritization, supporting the development of highly specific CAR and TCR-based immunotherapies.

Learn More →

AI-Powered Neoantigen Prediction Service for TCR-T Development

Creative Biolabs applies advanced AI algorithms to predict patient-specific neoantigens from genomic and transcriptomic data. This approach enables precise identification of immunogenic neoepitopes, supporting personalized TCR-T therapy development.

Learn More →

AI-Accelerated scFv Library Screening Service for CAR-T Development

Creative Biolabs utilizes AI-driven in silico high-throughput screening to rapidly evaluate large scFv libraries. Our platform identifies high-affinity, stable antibody fragments, accelerating binder discovery for next-generation CAR constructs.

Learn More →

AI-Enhanced TCR-pMHC Affinity Modeling Service

Creative Biolabs employs AI-based structural modeling to predict TCR–pMHC binding affinity and interaction stability. This technology enables rapid prioritization of potent TCR candidates for therapeutic development.

Learn More →

AI-Guided Epitope Mapping & Analysis Service

Creative Biolabs integrates neural network based structural prediction with epitope mapping algorithms to precisely identify antigen-binding sites. This enables improved receptor specificity and optimized immunotherapy design.

Learn More →

AI-Optimized Binder Humanization Service

Creative Biolabs applies AI-guided antibody humanization to reduce immunogenicity while maintaining binding affinity and structural stability, supporting the development of safer therapeutic binders for CAR and TCR applications.

Learn More →

Core Benefits

High-Precision Binder Selection: AI-driven screening of massive TCR/scFv libraries to find candidates with optimal specificity and minimal cross-reactivity.
3D Structural Modeling: Advanced residue-level contact prediction and protein-protein docking to visualize and refine pMHC-TCR interactions.
Pan-Allelic MHC Support: Predictive modeling covering thousands of HLA-I and HLA-II alleles, including underrepresented ethnic genotypes.
Integrated Multi-Task Learning: Models that simultaneously predict antigen presentation, TCR recognition, and binder stability for holistic lead optimization.

FAQs

Q: How does AI-driven discovery compare to traditional MS-based immunopeptidomics?

A: While mass spectrometry (MS) provides direct evidence of presented peptides, it requires large amounts of tumor tissue and cannot be used on fixed samples. AI-driven discovery requires only sequencing data and can predict rare antigens that MS might miss due to "flyability" biases.

Q: Can your platform handle MHC Class II targets?

A: Yes. While MHC-II is more complex due to open binding grooves and variable peptide lengths, our platform utilizes specialized algorithms to achieve high molecular coverage.

Q: How do you ensure the binders don't react with normal tissues?

A: We use AI to screen candidates against expansive healthy tissue databases and utilize structural prediction to identify potential cross-reactivity with self-antigens.

Q: What is the typical success rate of predicted neoantigens in functional assays?

A: Traditional affinity-only filters often see success rates as low as 2%. By incorporating AI-driven immunogenicity features, our integrated pipelines have demonstrated recall rates over 50%.

Partner with Us

Creative Biolabs is a global leader in providing end-to-end AI solutions for the next generation of cancer immunotherapies. From initial Target Identification using high-throughput immunogenomics to the Refinement of CAR/TCR Binders via 3D structural modeling, we empower your research with precision science and actionable data. Please contact us for detailed project discussions or to receive a customized quote.

Reference

Zheng, Jiayao et al. "The Application of Machine Learning on Antibody Discovery and Optimization." Molecules (Basel, Switzerland) vol. 29,24 5923. 16 Dec. 2024. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/molecules29245923

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.